PsyBio Therapeutics Corp. Share Price

Equities

PSYB.H

CA6936971044

Biotechnology & Medical Research

Delayed Toronto S.E. 09:54:13 29/03/2024 am IST 5-day change 1st Jan Change
0.01 CAD -.--% Intraday chart for PsyBio Therapeutics Corp. -.--% -.--%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Exceptional extension!
Take advantage of the offer
* See conditions on site

Financials

Sales 2021 - Sales 2022 - Capitalization 2.87M 3.92M 239M
Net income 2021 -11M -15M -916M Net income 2022 -4M -5.45M -333M EV / Sales 2021 -
Net cash position 2021 3.81M 5.19M 317M Net Debt 2022 135K 184K 11.21M EV / Sales 2022 -
P/E ratio 2021
-1.54 x
P/E ratio 2022
-0.59 x
Employees -
Yield 2021 *
-
Yield 2022
-
Free-Float 61.68%
More Fundamentals * Assessed data
Dynamic Chart
1 year
0.00
Extreme 0.00000000
0.04
3 years
0.00
Extreme 0.00000000
0.55
5 years
0.00
Extreme 0.00000000
0.90
10 years
0.00
Extreme 0.00000000
0.90
More quotes
PsyBio Therapeutics Corp. is a Canada-based biotechnology company. The Company is focused on discovering, designing and developing psycho-focused therapeutics to improve mental and neurological conditions. It is focused on understanding the value of tryptamines and other related psycho-targeted molecules as therapeutic candidates to improve mental and neurological health. The Company is engaged in research and development for occurring psychoactive tryptamines, which is originally discovered in different varieties of hallucinogenic mushrooms, other tryptamines and phenethylamines, and combinations thereof. The Company utilizes a bio-medicinal chemistry approach to therapeutic development, in which psychoactive compounds can be utilized as a template upon, which to develop precursors and analogs, both naturally and non-naturally occurring.
More about the company

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Equities
  3. PSYB.H Stock
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW